Mesoblast narrows interim loss to $56.4m on Ryoncil sales

The news: Biotech company Mesoblast posted an interim net loss after tax of USD40.2 million ($56.40 million), compared with a loss of USD47.9 million a year ago.

The numbers: Total revenue jumped to USD51.3 million from USD3.2 million a year ago, driven by the commercial launch of its cell therapy Ryoncil in the United States. Ryoncil generated gross sales of USD57 million during the period.

The company did not declare a dividend and clarified that it does not anticipate paying dividends in the foreseeable future.

The context: The company said continued growth in the Ryoncil sales, launched in April 2025, helped narrowed the net loss from the prior year. It said revenue generated from the product will be used to fund its growth pipeline.